The optimal timing of administration of dual antiplatelet therapy (DAPT) in acute ST-segment-elevation myocardial infarction patients is debated. Clinical trials have failed to demonstrate the superiority of pretreatment with P2Y12 inhibitors in ST-segment-elevation myocardial infarction, but they were not designed to assess hard clinical end points. We used data from the FAST-MI (French Registry on Acute ST-Segment-Elevation or Non-ST-SegmentElevation Myocardial Infarction) cohorts to determine 1-year survival and in-hospital outcomes in patients receiving DAPT, comparing prehospital versus in-hospital administration.
A lthough the use of aspirin and P2Y12 inhibitors for patients presenting with ST-segmentelevation myocardial infarction (STEMI) constitutes a class I recommendation in both American College of Cardiology/American Heart Association and European Society of Cardiology guidelines, 1,2 the optimal timing of their administration is still debated. 3 It has been studied mostly for P2Y12 inhibitors. The ATLANTIC trial (Administration of Ticagrelor in the Cath Lab or in the Ambulance for New ST Elevation Myocardial Infarction to Open the Coronary Artery) failed to demonstrate the superiority of prehospital administration of ticagrelor on reperfusion before percutaneous coronary intervention (PCI; primary end point), but reduced ischemic events after PCI, although the trial was too small to conclude on clinical outcomes. 4, 5 Recently, an analysis from the SWEDEHEART registry (Swedish WebSystem for Enhancement and Development of EvidenceBased Care in Heart Disease Evaluated According to Recommended Therapies) showed no difference in 30-day clinical events for pretreatment (not necessarily prehospital) with ticagrelor in STEMI patients, compared with its administration in the catheterization laboratory. 6 France has a highly developed prehospital emergency medical system (Service d'Aide Médicale Urgente), with fully equipped ambulances with an emergency physician on board capable of delivering any type of emergency treatment for patients presenting with acute myocardial infarction (AMI). Many of the emergency physicians deliver aspirin and P2Y12 inhibitors in the ambulance, right after STEMI is diagnosed. Whether this early management translates into improved survival in STEMI patients remains unknown. The aim of the present study was therefore to assess whether 1-year mortality differed in Service d'Aide Médicale Urgente-transported STEMI patients according to the timing of dual antiplatelet therapy (DAPT) delivery (prehospital versus in hospital) in 3 nationwide FAST-MI (French Registry on Acute ST-Segment-Elevation or Non-ST-Segment-Elevation Myocardial Infarction) performed between 2005 and 2015. [7] [8] [9] 
POPULATION AND METHODS

Study
Three nationwide French registries were conducted 5 years apart from 2005 to 2015: FAST-MI 2005 (NCT00673036), 7 FAST-MI 2010 (NCT01237418), 8 and FAST-MI 2015 (NCT02566200). 9 The methods used have been described previously and are detailed in Methods I in the Data Supplement. Briefly, their primary objectives were to evaluate the characteristics, management, and outcomes of AMI patients, as seen in routine clinical practice, on a country-wide scale.
The registries were built using a similar methodology and included consecutive AMI patients (STEMI or non-STEMI) admitted to coronary or intensive care units ≤48 hours of symptom onset, during a 1-month period (October to December). Prolongation for up to 1 additional month was possible in voluntary centers. AMI was defined by increased levels of cardiac biomarkers with either compatible symptoms or ECG changes.
For the present study, only patients with STEMI (diagnosed when ST elevation ≥1 mm was seen in at least 2 contiguous leads in any location on the index or qualifying ECG, or when presumed new left bundle branch block or new Q waves were observed), with a time from symptom onset to first call <12 hours, transported by the Service d'Aide Médicale Urgente with an intent to get primary PCI (ie, excluding patients who received intravenous fibrinolysis), and who received DAPT at the acute stage either prehospital or in hospital were included. Patients who got aspirin but no P2Y12 inhibitor in the ambulance but received both of these medications once in hospital were included in the in-hospital group.
The data, analytic methods, and study materials will not be made available to other researchers for purposes of reproducing the results or replicating the procedure,
WHAT IS KNOWN
• Dual antiplatelet therapy combining aspirin and a P2Y12 inhibitor is recommended for patients with ST-segment-elevation myocardial infarction.
• It limits the risk of stent thrombosis.
• When administered early, its effect on infarctrelated artery patency is the subject of controversy.
• Randomized trials of prehospital administration of P2Y12 inhibitors have yielded conflicting results and were not powered to assess effects on clinical events.
WHAT THE STUDY ADDS
• The French emergency medical system (Service d'Aide Médicale Urgente) is highly developed and has physicians in the ambulances, who can deliver any type of emergency care.
• About half the ST-segment-elevation myocardial infarction patients managed by Service d'Aide Médicale Urgente ambulances in nationwide surveys receive dual antiplatelet therapy in the prehospital setting.
• We found that prehospital administration of dual antiplatelet therapy was associated with improved survival compared with administration once the patients were admitted to the hospital.
• Because some residual confounding may have increased the magnitude of the potential benefit, a large randomized clinical trial assessing the impact of timing of dual antiplatelet therapy administration is warranted.
because of the complexity of the database. However, an extraction of the data could be made available on request to the corresponding author, after consent from the board of the French Society of Cardiology, which owns the data. The study was conducted in accordance with the guidelines on good clinical practice and the French data protection law. All patients were informed of the nature and aims of the surveys and provided written informed consent, and approval of the Comité de Protection des Personnes was obtained (Methods I in the Data Supplement).
Data Collection
Data on baseline characteristics, use of cardiac procedures, and medications administered prehospital, in the first 48 hours, and at discharge were collected on electronic case record forms, by research technicians sent on site for the purpose of the surveys.
Follow-up was centralized at the French Society of Cardiology. The primary study end point (all-cause mortality) was available in 99% of the population for each registry.
Study End Points
The primary end point of the study was all-cause mortality at 1 year. Secondary end points were in-hospital death, bleeding and ischemic complications, and 30-day death. Pre-and post-PCI Thrombolysis in Myocardial Infarction (TIMI) flow was also assessed.
Statistical Analysis
Continuous variables are reported as means (SDs) or medians (interquartile ranges), when appropriate. Discrete variables are described as counts and percentages. Groups were compared by Student t tests for continuous variables and χ 2 tests or Fisher exact tests for discrete variables. Odds ratios and hazard ratios (HRs) are presented with their 95% CIs. Kaplan-Meier curves for survival were compared using log-rank tests.
Correlates of 1-year survival were determined using a backward Cox multivariate analysis, with a P value of 0.05 for inclusion and 0.10 for exclusion. Cumulative hazard functions for each covariable were computed to assess proportionality, and collinearity was verified by calculating variance inflation factors. Three models were used to assess the association between prehospital administration of DAPT and 1-year mortality: model 1, adjusted on the GRACE score (Global Registry of Acute Coronary Events); and model 2, adjusted on demographic data, study year, type of institution, initial transfer, risk factors, comorbidity, previously used secondary prevention medications, time from symptom onset, type of AMI (anterior versus nonanterior), presence of atrial fibrillation on first (diagnostic) ECG, presence of conduction disturbances on first ECG, time of day and day of week of symptom onset, initial Killip class, GRACE score, out-of-hospital cardiac arrest, prehospital use of morphine, glycoprotein IIb/IIA inhibitors (GPI) and parenteral anticoagulants, actual performance of primary PCI, medications administered in the first 48 hours after AMI onset, and type of P2Y12 inhibitor used (clopidogrel versus prasugrel or ticagrelor). To avoid a healthy survivor bias, we also repeated the analyses in the population of patients surviving at 48 hours. Model 3 was adjusted on the propensity score for getting prehospital DAPT (see below). Analyses were repeated using forward stepwise analysis to check the consistency of the results.
In addition, a propensity score for getting prehospital rather than in-hospital DAPT was calculated using multiple logistic regression (using baseline characteristics of the patients listed in Table I in the Data Supplement, study year, medications used before the index event, hospital transfer, time from symptom onset, time of day and day of week of onset, presence of conduction disturbances or atrial fibrillation on first ECG, initial Killip class, outof-hospital cardiac arrest, GRACE score, location of AMI, actual performance of primary PCI, and concomitant medications received in the ambulance) and used to build 2 cohorts of patients (360 patients each) matched on the propensity score, using a greedy matching procedure; the C statistics for the propensity score was 0.92. The average standardized difference for the propensity score was −232.99% before and −0.48% after matching.
Statistical analyses were performed using IBM SPSS 25.0 (IBM SPSS Inc) and NCSS 10. For all analyses, a 2-sided P value <0.05 was considered to be statistically significant.
RESULTS
Baseline Characteristics
From an initial population of 6870 patients presenting with STEMI, 3548 met the inclusion criteria ( Figure I Overall, patients not receiving prehospital treatment were slightly older (64±14 versus 63±13 years), with more hypertension or diabetes mellitus, but less frequently current smokers; previous cardiovascular history did not differ markedly, and previous medications were essentially similar (Table 1) . Time from symptom onset was longer, and out-of-hospital cardiac arrest was more frequent in patients treated in hospital. Location of AMI was similar, but more patients were Killip class ≥2 at presentation, and GRACE score was higher in those not receiving prehospital DAPT. Coronary angiography was performed in 99.6% and 96.7%, respectively, with prehospital and in-hospital DAPT. Morphine use was more frequent in patients getting prehospital DAPT, and prasugrel and ticagrelor were used more often. Among the in-hospital group patients, 498 (25%) received aspirin without P2Y12 inhibitor in the ambulance. Patients with prehospital DAPT also received more statins, angiotensin-converting enzyme inhibitors or angiotensin receptor blockers, and newer anticoagulants (bivalirudin, fondaparinux) in the first 48 hours (Table 2 ).
In-Hospital Outcomes
TIMI 2 or 3 flow before PCI was similar in the 2 groups, and significantly more prehospital DAPT patients had TIMI 2 or 3 flow after PCI. There was no difference in reinfarction and stroke nor in development of cardiogenic shock after hospital admission. TIMI major or minor bleedings were also observed in similar proportions of patients. In-hospital death, however, was higher in patients who did not receive prehospital DAPT. Likewise, crude 30-day mortality was higher in patients getting treatment at a later stage (4.5% versus 2.1%, P<0.001).
One-Year Survival
One-year Kaplan-Meier survival was 95.1% in patients receiving prehospital DAPT, compared with 90.5% in those who received treatment in the hospital only (Figure 1 ). Crude HR for 1-year death was 0.50 (95% CI, 0.38-0.65; P<0.001). Subgroup analyses showed homogeneous results according to age, and whatever the STEMI location, timing of first call, out-of-hospital cardiac arrest, betweenhospital transfer, prehospital morphine use, actual performance of primary PCI, survey year, and type of P2Y12 inhibitor (Figure 2 ). In the in-hospital group, 1-year mortality was comparable in those who had received aspirin prehospital (8.8%) and in those who had not (9.7%).
After adjustment on the GRACE score, HR for 1-year death was 0.68 (0.51-0.89), and after full adjustment, HR was 0.69 (0.51-0.92), P=0.011; HR after adjustment on the propensity score was 0.55 (0.41-0.73), P<0.001 (Figure 1 ). After censoring patients dying during the first 2 days, to avoid a potential healthy survivor bias, fully-adjusted HR was 0.61 (0.45-0.83), P=0.002.
After propensity score matching, the 2 cohorts of 360 patients had similar baseline characteristics (Table I in the Data Supplement). In-hospital procedures and medications were also similar. There were no differences in in-hospital outcomes, including bleeding, and 30-day mortality was not significantly different, although numerically lower in patients with prehospital DAPT (2.5% versus 5.0% with in-hospital administration; odds ratio, 0.49; 95% CI, 0.22-1.10; Table  II in the Data Supplement). In the propensity scorematched cohorts, 1-year Kaplan-Meier survival was 93.9% in patients with prehospital DAPT and 90.3% in those with in-hospital DAPT; HR was 0.62 (95% CI, 0.36-1.05; P=0.077; Figure 3 ).
DISCUSSION
Main Findings
In these nationwide cohorts of patients presenting within 12 hours of STEMI onset and transported by physician-staffed emergency medical system ambulances in view of performing primary PCI, prehospital administration of DAPT was associated with improved 1-year survival. Consistent results were observed across subgroups. Thirty-day mortality was not significantly different after adjustment, although numerically lower, and in-hospital bleeding was similar whatever the timing of DAPT administration. Data are presented as n (%) or mean±SD. ACE indicates angiotensin-converting enzyme; ARB, angiotensin receptor blocker; DAPT, dual antiplatelet therapy; LMWH, low molecular weight heparin; MI, myocardial infarction; PCI, percutaneous coronary intervention; and TIMI, Thrombolysis in Myocardial Infarction.
Previous Studies on Timing of DAPT and P2Y12 Inhibition in STEMI Patients
The benefit of pretreatment with P2Y12 inhibitors and aspirin in patients with primary PCI for STEMI is still a matter of debate.
3 From a theoretical standpoint, earlier administration of antiplatelet agents is more likely to provide improved antiplatelet activity at the time and immediately after primary PCI. Thirty years ago, the ISIS-2 trial (Second International Study of Infarct Survival) showed a 23% odds reduction in vascular mortality in patients receiving a 160 mg dose of aspirin for AMI, and aspirin and streptokinase had a synergistic effect. 10 More recent trials have assessed the effect of P2Y12 inhibitors on top of aspirin. The CIPAMI trial (Clopidogrel to Improve Primary Percutaneous Coronary Intervention in Acute Myocardial Infarction) 11 showed similar pre-PCI patency in patients receiving 600 mg clopidogrel pretreatment for STEMI, compared with those receiving clopidogrel after coronary angiography, but there were numerically fewer ischemic events in patients pretreated. The largest clinical trial testing the impact of prehospital administration of a P2Y12 inhibitor on top of aspirin was the ATLANTIC trial.
5 It failed to demonstrate the superiority of prehospital administration of ticagrelor on pre-PCI TIMI flow and ST-segmentelevation resolution; a trend favoring pretreatment was observed for platelet inhibition and ST-segment resolution 1 hour after the procedure. In patients who underwent PCI, there was a reduction in stent thrombosis at 30 days, as well as a reduction in ischemic events in pretreated patients; also, there was no significant difference in mortality (but a numeric excess in early deaths), and there was no bleeding excess in the pretreatment group. These results were confirmed in a recent meta-analysis of 7 randomized studies which compared early versus delayed P2Y12 inhibition in 9648 STEMI patients undergoing PCI; early P2Y12 inhibition in PCI of STEMI improved coronary reperfusion before PCI and reduced MACE, MI and bailout GPI use, without increase in major bleeding. Several observational studies also assessed the potential impact of pretreatment with P2Y12 inhibitors in STEMI patients. The definition of pretreatment differed among studies, some limiting comparisons to ambulance administration (as we did), whereas others defined pretreatment as administration at any time before coronary angiography. In a single-center cohort from Zwolle, ambulance administration of high-dose clopidogrel (600 mg) was not associated with improved infarct-related patency nor early death, compared with in-hospital administration. 13 Likewise, in a multicentre Australian cohort, pretreatment with P2Y12 inhibitors (80% clopidogrel) was not associated with higher infarct-related artery patency, nor increased risk of bleeding; 12-month mortality was lower, but only a nonsignificant difference persisted after multivariate adjustment.
14 In contrast, in a previous analysis from the FAST-MI 2010 cohort, we found that ambulance administration of prasugrel or glycoprotein IIB/IIIa inhibitors was an independent correlate of infarct-related artery patency in patients undergoing primary PCI. 15 Recently, a report from the SWEDEHEART registry analyzed clinical and angiographic correlates of pretreatment with ticagrelor, compared with administration in the catheterization laboratory in STEMI patients undergoing primary PCI. 6 Among the 7433 patients included, 73% received pretreatment, among whom 98% received aspirin concomitantly. At 30 days, there was no reduction in a composite end point of death, recurrent myocardial infarction, or stent thrombosis (6.2% versus 6.5%), nor in any of its components; there was no increase in bleeding during the hospital stay associated with pretreatment. A broad definition of pretreatment (ie, not limited to prehospital administration) was used, and the difference in timing of ticagrelor administration was not known. Long-term outcomes were not studied.
Besides the fact that we considered treatment in the ambulance, rather than the broader definition of pretreatment (treatment before coronary angiography), the main difference between the present study design and previous reports is that we included all STEMI patients transported by emergency medical service, irrespective of the actual performance of primary PCI. We only excluded patients receiving fibrinolytic treatment, thereby reflecting that the actual choice emergency physicians are confronted with in the ambulance. Also, the present cohort is the largest to have assessed longterm survival. Both considerations might explain why we found larger differences than previously observed.
Subgroups
Consistent results were found in most subgroups. In particular, prehospital administration was associated with improved survival in all 3 surveys, in elderly patients as in younger patients, and whether the patients were seen early or later on. No difference was found according to the presence of out-of-hospital cardiac arrest or prehospital morphine use or to the type of P2Y12 inhibitor used. Morphine may interfere with absorption of P2Y12 inhibitors. An ancillary study of the ATLANTIC trial showed that morphine administration was associated with delayed onset of action of ticagrelor. 16 In terms of clinical events (in-hospital complications and 1-year mortality), however, we found no deleterious impact of prehospital administration of morphine. 17 Several studies have compared platelet reactivity, coronary artery patency before primary PCI, and clinical events between the different P2Y12 inhibitors, with discrepant results. [18] [19] [20] [21] [22] [23] [24] To the best of our knowledge, prasugrel pretreatment versus administration after coronary angiography has not been studied in a dedicated study in STEMI patients. In the ATLANTIC trial, 5 the median time difference between prehospital and catheterization laboratory administration of ticagrelor was only 31 minutes, which made demonstration of any clinical difference before PCI difficult, but was nevertheless associated with differences after PCI in terms of platelet function, ST-segment resolution, and clinical outcomes. 4 Of note, we found a higher rate of TIMI 2/3 flow after the procedure in patients who had undergone primary PCI and had received prehospital treatment.
Limitations
The present analysis is a retrospective analysis of prospectively collected data. As for all observational studies, causality between timing of DAPT and 1-year survival cannot be inferred. However, we did adjust for a large number of parameters, and concordant findings were observed with 3 types of adjustments, including adjustment on a propensity score for getting prehospital DAPT. In the propensity score-matched cohorts, however, the difference in 1-year survival was not statistically significant (P=0.077); because the Cox analysis adjusted on the propensity score in the whole population was statistically significant, it seems plausible that the lack of statistical significance in the matched cohorts may have been because of lack of statistical power. The observed difference in 1-year mortality is high, and not readily explained, as there was no difference in TIMI flow before the procedure, and no decreased risk of stent thrombosis or nonfatal recurrent myocardial infarction; in-hospital mortality was numerically lower, however, and death resulting from MI recurrence may have been recorded as in-hospital death rather than AMI recurrence. Because of the lack of evident impact on initial TIMI flow and stent thrombosis, as well as of the magnitude of the decrease in 1-year mortality, we cannot exclude, however, that some degree of residual confounding might have participated in the results observed.
Because only patients with confirmed AMI are included in the FAST-MI registries, we cannot assess potentially deleterious effects of erroneous use of DAPT pretreatment in some patients in whom they should be avoided (eg, aortic dissection, pericarditis). Furthermore, the precise timing of DAPT administration was not recorded in the surveys. In the 2010 and 2015 surveys, however, timing of diagnostic ECG was recorded, and median time from ECG to hospital admission in patients receiving DAPT in the ambulance was 50 minutes, suggesting that DAPT administration would have a head start of at least 50 minutes compared with in-hospital administration, a difference 50% larger than that in the ATLANTIC trial.
CONCLUSIONS
In the present study, analyzing data from 3 nationwide cohorts over the 2005 to 2015 period, prehospital administration of DAPT in STEMI patients presenting within 12 hours of symptom onset and considered for a primary PCI strategy was associated with higher 1-year survival, compared with in-hospital administration. In line with previous studies, prehospital administration was not associated with increased risk of bleeding. These data confirm the lack of hazard associated with administration of DAPT in the ambulance for STEMI patients and suggest a favorable impact on long-term outcome. The magnitude of the decrease in 1-year mortality, however, may suggest the persistence of some degree of residual confounding. Because STEMI remains a major public health concern, and because timing of DAPT administration may have an impact on long-term outcomes, a contemporary randomized clinical trial to address this issue is certainly warranted.
